Asia Pacific and Russia diagnostic study for EGFR testing - IGNITE

Study identifier:D7913C00074

ClinicalTrials.gov identifier:NCT01788163

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies

Medical condition

EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies.

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

3500

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 27 Feb 2013
Primary Completion Date: 25 Aug 2014
Study Completion Date: 20 Jun 2016

Study design

Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Verification:

Verified 01 Oct 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria